Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.

Participate in Clinical Trials

In The News

Intralytix Receives USDA, NIFA Phase III SBIR Grant To Optimize Application of Its Salmonella-Targeting Bacteriophage Preparation SalmoFresh™ at Poultry and Meat Producers

Intralytix, Inc., announced today that it has received a SBIR Phase III grant (Award No. 2023-70439-39191) from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA)'s Meat and Poultry Processing Research and Innovation Program, to optimize SalmoFresh™ application at small and medium poultry and meat producers.

Intralytix Launches Phase 1/2a Phage Therapy Trial to Prevent Illness Caused by Shigella

Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of Intralytix phage therapy product ShigActive™ to prevent or reduce the severity of Shigella infections.

H.C. Wainwright & Co., LLC hosts the First Annual Bacteriophage Conference

On November 30, 2022, H.C. Wainwright & Co., LLC hosted the First Annual Bacteriophage Conference to highlight what H.C. Wainwright & Co. believes to be a major pending inflection point in the field. Intralytix was one of the phage companies featured at the conference, with our President and CEO, Dr. Alexander "Sandro" Sulakvelidze presenting.

Intralytix receives Phase II Fast Track NIH SBIR contract to continue development of a universal, scale-independent AI-based platform for manufacturing high titer bacteriophage preparations for clinical applications.

Intralytix, Inc. announced today that it has received a Phase II contract in the amount of $1,498,045. This contract is made through the Small Business Innovation Research (SBIR) program from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This project is the continuation of a successfully completed NIAID-funded Phase I contract.

See more...


Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics